tbuckley/cabot-search huggingface dataset:
Sorbitol Dehydrogenase and Hepatocellular Injury: An Experimental and Clinical Study
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health Agencies Update
Authors: Joan Stephenson
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality
Authors: J. Stephenson
Journal: JAMA (1995)

TWO LONG-AWAITED trials of drugs to treat HIV disease and AIDS are yielding results that may prompt a shift away from using AZT (formally known as zidovudine) monotherapy as a first-line treatment for the viral infection. Speaking to a standing-room-only crowd at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in San Francisco, Calif, last month, researchers from Harvard Medical School, Boston Mass, and Stanford (Calif) University School of Medicine described surprising findings from AIDS Clinical Trial Group 175 (ACTG 175), a multicenter study of nearly 2500 participants. The trial found that AZT, the oldest and most widely prescribed drug for the infection, is less effective in patients with intermediate disease than monotherapy with an alternative antiretroviral drug, didanosine (also called ddI), or than regimens that combine AZT with ddI or another nucleoside analog, zalcitobine (also called ddC). "The finding that treatment in intermediate-stage HIV disease can
Environmental and public health
Authors: T. C. Doege
Journal: JAMA (1980)

Startling advances in public health contrasted with some less favorable developments during the 1970s, but the general trend was one of progress, including progress with some problems of major public health significance. <h3>Immunization</h3> Prevention of infectious diseases through immunization has always been a primary aim in public health. During the 1970s a strong effort by workers of many nations, which was spearheaded by some imaginative and energetic US epidemiologists, combined a decades-old vaccine, an approach emphasizing outbreak control and interruption of transmission, and improvements in vaccination techniques to produce for the first time the worldwide eradication of an infectious disease, smallpox.<sup>1,2</sup> There were other important developments concerning immunizing agents: Rho(D) immune globulin was licensed in 1968, and from 1970 to 1977, Rh hemolytic disease of the newborn decreased in the United States from 41 cases per 10,000 births to 19 cases per 10,000 births, a decline of 54%.<sup>3</sup>
Arztliche Fragen: Vorlesungen über allgemeine Therapie
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the National Institutes of Health
Authors: William Raub
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways
Authors: Davide Ciardiello, Pietro Paolo Vitiello, Nunzia Matrone, Valentina Belli, Claudia Cardone, Luca Poliero, Carola Borrelli, Gianluca Arrichiello, Giulia Martini, Vincenza Ciaramella, Giusi Barra, Floriana Morgillo, Teresa Troiani, Davide Melisi, Fortunato Ciardiello, Erika Martinelli
Journal: Cancer Research (2019)

Abstract According to the consensus molecular subtypes (CMS), almost 23% of human colorectal cancer (CRC) are classified in the CMS4 group, characterized by a mesenchymal signature and the activation of transforming growth factor β (TGF-β) signaling. AXL is a tyrosine kinase receptor involved in epithelial to mesenchymal transition, angiogenesis and immune modulation in CRC. We have previously demonstrated that AXL gene is amplified in approximately 5% of human CRC, and that AXL inhibition causes a significant blockade of CRC cell proliferation and migration. Here we have evaluated the role of TGF-β signaling and the potential interaction between TGF-β and AXL in human CRC cell lines. We assessed the expression and activation of TGF-β and AXL in a panel of six human CRC cell lines by western blot (WB) and real time PCR. We tested the sensitivity of HCT116 and LOVO cells to treatment with galunisertib ( LY21209761), a selective TGF-β R1 inhibitor, by MTT, cell invasion, wound healing and soft-agar colony forming assays. Further, intracellular CRC cell signaling was evaluated following galunisertib treatment by WB. TGF-β receptors 1 and 2 were expressed in all human CRC cell lines (HCT116, SW480, LOVO, LIM 1215, SW48 and CaCo2), whereas AXL expression was restricted to HCT116, SW480, LOVO cells. Treatment with galunisertib had little or no effect on cancer cell growth, whereas it partially reduced TGF-β induced cell migration, invasion and colony formation in HCT116 and LOVO cells (that co-expressed both TGF-β receptors and AXL). Interestingly, TGF-β inhibition resulted in a concomitant significant activation of AXL and p38 MAPK in both cell lines, that could represent a cancer cell adaptive mechanism of resistance to galunisertib treatment. These results suggest a potential functional cross talk between TGF-β, AXL and p38 MAPK signals in human CRC cells. In this respect, further experiments are ongoing to better understand this interaction with the aim of identifying potential novel anti-AXL and anti-TGF-β therapeutic strategies. Citation Format: Davide Ciardiello, Pietro Paolo Vitiello, Nunzia Matrone, Valentina Belli, Claudia Cardone, Luca Poliero, Carola Borrelli, Gianluca Arrichiello, Giulia Martini, Vincenza Ciaramella, Giusi Barra, Floriana Morgillo, Teresa Troiani, Davide Melisi, Fortunato Ciardiello, Erika Martinelli. Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2627.
ACCF/AHA Clinical Practice Guideline Methodology Summit Report
Authors: Alice K Jacobs, Frederick G Kushner, Steven M Ettinger, Robert A Guyton, Jeffrey L Anderson, E Magnus Ohman, Nancy M Albert, Elliott M Antman, Donna K Arnett, Marnie Bertolet, Deepak L Bhatt, Ralph G Brindis, Mark A Creager, David L DeMets, Kay Dickersin, Gregg C Fonarow, Raymond J Gibbons, Jonathan L Halperin, Judith S Hochman, Marguerite A Koster, Sharon-Lise T Normand, Eduardo Ortiz, Eric D Peterson, William H Roach, Ralph L Sacco, Sidney C Smith, William G Stevenson, Gordon F Tomaselli, Clyde W Yancy, William A Zoghbi
Journal: Circulation (2012)
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
Authors: Vinod Ravi, Andrew Scott Brohl, Sant P. Chawla, Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, Atrayee Basu Mallick, Cyrus R. Mehta, Lingyun Liu, Delia Alvarez, Charles P. Theuer, Steven Ian Robinson, Nicolas Penel, Silvia Stacchiotti, William D. Tap, Robin Lewis Jones, Robert G. Maki
Journal: Journal of Clinical Oncology (2018)

TPS11590 Background: Angiosarcoma (AS) is an aggressive soft tissue sarcoma (STS) of endothelial origin with reported median OS of 8-12 months. Pazopanib (P) is approved for treatment of advanced STS refractory to an anthracycline. In a retrospective study of 40 AS patients treated with single agent P, median PFS was 3.1 months and median OS 9.9 months with a low response rate and no complete responses. Endoglin is an essential angiogenic receptor expressed on AS that is upregulated following VEGF inhibition. TRC105, an endoglin antibody, combined with P achieved durable complete responses in two of 18 AS patients, with median PFS of 7.8 months in chemotherapy-refractory and P-naïve patients enrolled in a Phase 1/2 trial. The TAPPAS Phase 3 trial was initiated following protocol assistance from the EMA and Special Protocol Assessment from the FDA. Methods: TAPPAS (NCT02979899) is a randomized multicenter study of TRC105/P vs P alone actively enrolling cutaneous and non-cutaneous AS patients at > 25 sites in the United States and Europe, and incorporates an adaptive enrichment design. Key inclusion criteria: 0, 1 or 2 prior lines of therapy, ECOG ≤ 1. Primary endpoint is PFS. Secondary endpoints include ORR and OS. The initial sample size of 124 patients, followed until 95 PFS events, provides more than 80% power to detect a hazard ratio of 0.55. At the time of interim analysis, projected to occur upon the occurrence of 40 events in approximately 70 patients, the trial will be classified as belonging to either the favorable, promising, enrichment or unfavorable zones, based on conditional power. Sample size and PFS events will be unchanged in the favorable and unfavorable zones, and will be increased to a total of 200 patients followed for 170 events in the promising zone. The trial will enroll a total of 135 patients with cutaneous disease followed for 110 events in the enrichment zone. An independent Data Monitoring Committee will follow the trial for safety and futility and recommend sample size or population adaptation. The adaptive design permits enrollment of fewer and more responsive patients over a shorter time compared to a fixed sample size design, while preserving type-1 error. Clinical trial information: NCT02979899.
Inadvertent Misadministration of Meningococcal Conjugate Vaccine—United States, June-August 2005
Journal: JAMA (2006)

During June-August 2005, CDC and the Food and Drug Administration (FDA) were notified of seven clusters of inadvertent subcutaneous (SC) misadministration of the new meningococcal conjugate vaccine (MCV4, Menactra) (Sanofi Pasteur, Inc., Swiftwater, Pennsylvania), which is licensed for intramuscular (IM) administration only. A total of 101 persons in seven states were reported to have received MCV4 by the SC route. Of these, 100 were contacted by their health-care providers and advised of the administration error. CDC conducted an investigation to determine whether SC administration of MCV4 resulted in a protective immunologic response. This report describes the results of that investigation, which indicated that, despite the misadministration, persons vaccinated by the SC route were sufficiently protected and that revaccination was not necessary.
Aspiration of food by psychiatric patients
Authors: M. H. Wendkos
Journal: JAMA (1982)

<h3>To the Editor.—</h3> Previous studies have shown that certain risk factors for bacteremia are applicable to young, febrile patients who make their first visit to an inner-city "walk-in" clinic and are discharged, with or without antimicrobial therapy. Such patients have no focus of infection, an upper respiratory tract infection, pharyngitis, otitis media, or pneumonia, and are not ill enough to be hospitalized. The three risk factors for outpatientbacteremia in this setting are an age between 6 months and 24 months, WBC count of 15,000/cu mm or greater, and a temperature of 38.9 °C or higher.<sup>1</sup> Although one study<sup>2</sup>suggests a similar incidence of bacteremia in such patients in private pediatric practice, how the preceding data relate to a private practice setting remains unclear.<sup>3</sup> A mail survey was conducted to determine how practicing pediatricians on the voluntary staff of the Nassau County Medical Center treat their "patients
RESUSCITATION IN APPARENT ASPHYXIA OR DROWNING.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lymphocyte Ontogeny and Activation in Gene Targeted Mutant Mice
Authors: K. Pfeffer
Journal: Annual Review of Immunology (1994)

Gene targeting by homologous recombination in pluripotent embryonic stem cells enabled the systematic creation of mouse strains with defined genetic alterations. During the past few years a rapidly growing number of gene targeted mice has provided new insights into development, selection, activation, and signaling of T and B cells, as well as into the functions of cytokines. Here we discuss the present state of targeting technology and summarize the phenotypic changes observed in gene targeted mouse strains of immunological interest. These data allow us for the first time to define genetic checkpoints in lymphocyte development that are crucial for the orderly progression of T and B cells through ontogeny and for the generation of an immune response.
Virtual Colonoscopy
Authors: Steve Halligan, Stuart Taylor, David Burling
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doing Everything
Authors: David S. Pisetsky
Journal: Annals of Internal Medicine (1999)

Letters19 January 1999Doing EverythingDavid S. Pisetsky, MD, PhDDavid S. Pisetsky, MD, PhDDurham Veterans Affairs Medical Center; Durham, NC 27707Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-130-2-199901190-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:My account of my father's death, “Doing Everything,” concluded with the two sentences, “I am only a physician. I can do nothing at all.” These words came to me spontaneously as I was writing. I tried to change them many times during rewriting because they seemed so stark and defeated. They are also contrary to my own aspirations as a physician. No physician would like to admit that he or she is unable to act.I nevertheless used this language fully in recognition of the points made by Dr. Knudsen. Clearly, as Dr. Knudsen observes in her thoughtful ... Author, Article, and Disclosure InformationAffiliations: Durham Veterans Affairs Medical Center; Durham, NC 27707 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDoing Everything David S. Pisetsky Doing Everything Nancy S. Knudsen Metrics 19 January 1999Volume 130, Issue 2Page: 165-166KeywordsMotivation Issue Published: 19 January 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Myotonic dystrophy and leukemia
Authors: J. F. Fraumeni
Journal: JAMA (1969)

<h3>To the Editor:—</h3> The clinician, who finds two or more uncommon and seemingly unrelated diseases in the same person, may wonder if the concurrence is simply coincidental or has larger significance. Should one of the diseases be of unknown origin, recognition of the association may provide clues to its etiology. Thus, case reports linking certain congenial cytogenetic disorders with leukemia suggest that chromosomal defects are involved in leukemogenesis.<sup>1</sup>We recently observed chronic granulocytic leukemia developing in a patient with myotonic dystrophy, a genetically determined disease not previously described with leukemia. <h3>Report of a Case:—</h3> A 47-year-old woman was admitted to the National Cancer Institute in October 1967 with the diagnosis of chronic granulocytic leukemia. Evaluation revealed massive splenomegaly, a leukocyte count of 302,000/cu mm, and bone marrow studies showing granulocytic hyperplasia and the Philadelphia chromosome. She also had far-advanced myotonic dystrophy, with characteristic facies and muscle weakness, cataracts bilaterally, and
Staff Author Cited Incorrectly.
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal